SGLT-2 Inhibitors
Top Diabetes Drugs Anticipated To Get Lower Medicare Pricing
Since the passage of the Inflation Reduction Act in 2022, the federal government has been able to negotiate the prices it pays for high-cost prescription drugs covered under Medicare. Lower prices for 15 medications – including Ozempic, Wegovy, and Rybelsus – have been negotiated for 2027 as part of ongoing Medicare drug price negotiations.
Trial Tests New Drug Combo To Reduce Cardiovascular Risk in Type 2
If you have type 2 diabetes, high blood pressure, and cardiovascular disease without a history of heart failure, you may be eligible for a clinical trial testing whether a new investigational drug taken with Jardiance can reduce the risk of heart-related issues.
Brenzavvy, a Type 2 Diabetes Drug, Available for Less Than $50 Month
New study in Diabetes, Obesity and Metabolism reveals Brenzavvy, an affordable SGLT-2 inhibitor for type 2 diabetes, is heart-safe and effective. It lowers blood sugar and A1C levels, reducing diabetes complications risk.
Diabetes Drugs Show Promise for Reducing Dementia Risk
A growing body of evidence suggests that the drug class called SGLT2 inhibitors join other diabetes drugs in offering protection from neurodegenerative diseases.
Diabetes Challenges, the Search for a Cure, and How to Help
Researchers, advocates, and people with diabetes offer guidance for dealing with daily difficulties, plus how to get involved in the next breakthrough treatments.
Why Diabetes Miracle Drugs like Ozempic Are Off-Limits to Type 1s
Exploring drugs like Ozempic and Farxiga for type 1 diabetes: potential benefits, safety concerns, and off-label use challenges. Discover how these medications could transform diabetes management.